Cargando…

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib

BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an ultra‐rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK‐targeting agents based on fusion partner is limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunga, Cass G. G., Higgins, Michael S., Ricciotti, Robert W., Liu, Yajuan J., Cranmer, Lee D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026288/
https://www.ncbi.nlm.nih.gov/pubmed/36754839
http://dx.doi.org/10.1002/cnr2.1792
_version_ 1784909511837876224
author Sunga, Cass G. G.
Higgins, Michael S.
Ricciotti, Robert W.
Liu, Yajuan J.
Cranmer, Lee D.
author_facet Sunga, Cass G. G.
Higgins, Michael S.
Ricciotti, Robert W.
Liu, Yajuan J.
Cranmer, Lee D.
author_sort Sunga, Cass G. G.
collection PubMed
description BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an ultra‐rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK‐targeting agents based on fusion partner is limited. CASE: A 30‐year‐old female sought emergency care after onset of abdominal and lower back pain in 2019. Computed tomography (CT) demonstrated a cystic, mesenteric mass within the pelvis measuring up to 8.9 cm. Complete laparoscopic excision of the mass from the mesentery of the right colon and terminal ileum was performed. Pathologic assessment revealed IMT with a fusion between sequestosome 1 and ALK (SQSTM1::ALK), described in only two other cases of IMT. Four months after surgery, CT revealed multi‐focal, unresectable disease recurrence. She was referred to the University of Washington/Fred Hutchinson Cancer Center and placed on therapy with alectinib, after which she experienced a partial response. Three years after IMT recurrence, disease remains under control. CONCLUSION: This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Treatment with the ALK inhibitor alectinib appears to be active in this setting.
format Online
Article
Text
id pubmed-10026288
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100262882023-03-21 Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib Sunga, Cass G. G. Higgins, Michael S. Ricciotti, Robert W. Liu, Yajuan J. Cranmer, Lee D. Cancer Rep (Hoboken) Case Reports BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an ultra‐rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK‐targeting agents based on fusion partner is limited. CASE: A 30‐year‐old female sought emergency care after onset of abdominal and lower back pain in 2019. Computed tomography (CT) demonstrated a cystic, mesenteric mass within the pelvis measuring up to 8.9 cm. Complete laparoscopic excision of the mass from the mesentery of the right colon and terminal ileum was performed. Pathologic assessment revealed IMT with a fusion between sequestosome 1 and ALK (SQSTM1::ALK), described in only two other cases of IMT. Four months after surgery, CT revealed multi‐focal, unresectable disease recurrence. She was referred to the University of Washington/Fred Hutchinson Cancer Center and placed on therapy with alectinib, after which she experienced a partial response. Three years after IMT recurrence, disease remains under control. CONCLUSION: This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Treatment with the ALK inhibitor alectinib appears to be active in this setting. John Wiley and Sons Inc. 2023-02-08 /pmc/articles/PMC10026288/ /pubmed/36754839 http://dx.doi.org/10.1002/cnr2.1792 Text en © 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Sunga, Cass G. G.
Higgins, Michael S.
Ricciotti, Robert W.
Liu, Yajuan J.
Cranmer, Lee D.
Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
title Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
title_full Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
title_fullStr Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
title_full_unstemmed Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
title_short Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
title_sort inflammatory myofibroblastic tumor of the mesentery with a sqstm1::alk fusion responding to alectinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026288/
https://www.ncbi.nlm.nih.gov/pubmed/36754839
http://dx.doi.org/10.1002/cnr2.1792
work_keys_str_mv AT sungacassgg inflammatorymyofibroblastictumorofthemesenterywithasqstm1alkfusionrespondingtoalectinib
AT higginsmichaels inflammatorymyofibroblastictumorofthemesenterywithasqstm1alkfusionrespondingtoalectinib
AT ricciottirobertw inflammatorymyofibroblastictumorofthemesenterywithasqstm1alkfusionrespondingtoalectinib
AT liuyajuanj inflammatorymyofibroblastictumorofthemesenterywithasqstm1alkfusionrespondingtoalectinib
AT cranmerleed inflammatorymyofibroblastictumorofthemesenterywithasqstm1alkfusionrespondingtoalectinib